Obtenção de compósitos hidroxiapatita-quitosana contendo sulfadiazina de prata complexada em ß-ciclodextrina

• Ano de defesa: 2015
• Autor(a) principal: Trindade, Gabriela das Graças Gomes
• Orientador(a): Nunes, Rogéria de Souza
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Sergipe
• Programa de Pós-Graduação: Pós-Graduação em Ciências Farmacêuticas
• País: BR
• Palavras-chave em Português: Farmácia; Quitosana; Hidroxiapatita; Compósitos poliméricos; Sulfadiazina de prata; Sistemas de liberação
• Palavras-chave em Inglês: Composites; Chitosan; Silver sulfadiazine; Delivery systems
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::FARMACIA
• Link de acesso: https://ri.ufs.br/handle/riufs/3932

The use of composites containing bioceramics and polymers in order to combine the advantages isolated materials, with the aim of producing a system with suitable mechanical characteristics for drug delivery has been widely studied in recent years. Thus, the aim of this work was to develop hydroxyapatite-chitosan composites containing silver sulfadiazine, an antibiotic of choice for treatment of burns and skin extensive wounds, complexed in β-cyclodextrin. The composites were obtained by solvent evaporation method. In order to improve the solubility of the silver sulfadiazine in an aqueous medium, inclusion complexes were obtained by paste method, at different stoichiometric ratios silver sulfadiazine/β-cyclodextrin (1:1, 1:2 and 1:3), respectively. After procurement, the complexes, composites and its individual components were characterized by differential scanning calorimetry, thermogravimetry, Fourier transformed infrared, X-ray diffraction and scanning etectron microscopy. The development of the assay method and the drug complexation efficiency was performed by high performance liquid chromatography. The characterization results of the components, physical mixture and inclusion complexes obtained, allowed us to visualize the interaction between the drug and β-cyclodextrin, suggesting complexation. The characterization results of the components and composites showed possible interactions between hydroxyapatite, chitosan and inclusion complexes demonstrating that there was formation of the composite after incorporation of the drug. The drug assay method was developed and showed a linear response in the concentration range from 0.003 to 0.03 mg/mL, with r² = 0.9996, and the test showed precision, accuracy, quantification limit, detection limit and robustness adequate for investigation of drug dosing. The inclusion complexes 1:1 had higher complexation efficiency of silver sulfadiazine in β-cyclodextrin (32.15%). Thus, the stoichiometric ratio 1:1 proved to be sufficient for formation of the inclusion complex of silver sulfadiazine/β-cyclodextrin, and subsequently was favorable to be incorporated into the hydroxyapatite/chitosan composites.